15.94
6.41%
+0.96
Avalo Therapeutics Inc stock is currently priced at $15.94, with a 24-hour trading volume of 78,131.
It has seen a +6.41% increased in the last 24 hours and a +244.71% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $14.98 pivot point. If it approaches the $16.32 resistance level, significant changes may occur.
Previous Close:
$14.98
Open:
$15
24h Volume:
78,131
Market Cap:
$16.48M
Revenue:
$1.93M
Net Income/Loss:
$-31.54M
P/E Ratio:
-7.4486
EPS:
-2.14
Net Cash Flow:
$-30.68M
1W Performance:
+37.06%
1M Performance:
+244.71%
6M Performance:
+15,139%
1Y Performance:
+427.81%
Avalo Therapeutics Inc Stock (AVTX) Company Profile
Name
Avalo Therapeutics Inc
Sector
Industry
Phone
410 522 8707
Address
540 Gaither Road, Suite 400, Rockville
Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-24-21 | Initiated | RBC Capital Mkts | Outperform |
Avalo Therapeutics Inc Stock (AVTX) Latest News
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
Benzinga
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
Zacks Investment Research
Why VirTra Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
GlobeNewswire Inc.
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Avalo Therapeutics Inc Stock (AVTX) Financials Data
Avalo Therapeutics Inc (AVTX) Revenue 2024
AVTX reported a revenue (TTM) of $1.93 million for the quarter ending December 31, 2023, a -89.34% decline year-over-year.
Avalo Therapeutics Inc (AVTX) Net Income 2024
AVTX net income (TTM) was -$31.54 million for the quarter ending December 31, 2023, a +24.28% increase year-over-year.
Avalo Therapeutics Inc (AVTX) Cash Flow 2024
AVTX recorded a free cash flow (TTM) of -$30.68 million for the quarter ending December 31, 2023, a -14.28% decrease year-over-year.
Avalo Therapeutics Inc (AVTX) Earnings per Share 2024
AVTX earnings per share (TTM) was -$382.19 for the quarter ending December 31, 2023, a +64.05% growth year-over-year.
About Avalo Therapeutics Inc
Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis. Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Cap:
|
Volume (24h):